Vitalhub Corp (VHIBF) Fair Value & Analysis
Healthcare · US · Market cap $310M
Fair value as of: Jun 25, 2026
Analysis
Vitalhub Corp (VHIBF) currently trades at $4.90, while our model-based Fair Value estimate is $2.40 — implying the stock looks roughly 51.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Vitalhub Corp., together with its subsidiaries, provides technology and software solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. The company offers patient flow, operational visibility, and patient journey optimization solutions for hospital and integrated health environments, including SHREWD, Intouch with Health, Strata Health, MedCurrent, Beautiful Information, My Pathway, BookWise Solutions, Jayex Acute, MCAP, and Oculys. It also provides electronic healthcare record, case management, care coordination, and optimization solutions to inpatient/outpatient care providers, long-term care, and community and social services focused organizations, such as TREAT, CaseWORKS, clarity, Community Data Solutions, S12, B Care, DOCit, hicom, Clarity Healthcare Solutions, and Pirouette. In addition, the company offers a workforce automation and compliance suite that integrates and centralizes workfo…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Vitalhub Corp (VHIBF) undervalued?
What is the fair value of VHIBF?
What is the quality score of VHIBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.